Open-Label Treatment for Attention Deficit Hyperactivity Disorder (ADHD) (ADHD Trial)

"The primary outcome that will be evaluated over a 4 week period is the prevalence of adverse effects from PM dosage. Secondary outcomes include evaluation of Morning ADHD symptoms and Global assessment of severity of illness during AM dosing, as gauged by Parent-Rated ADHD Rating Scale, 5th Edition (PR-ADHD-RS-5) Total Score and Clinical Global Impression - Severity of Ilness (CGI-S) Scale respectively. The lower scores in both cases indicate more positive results."

"Affirmative. Clinicaltrials.gov's records demonstrate that this health research trial, which was first advertised on July 27th 2021, is searching for applicants now. 60 participants will be accepted at one medical institution."

"The clinical trial is currently enrolling, with initial postings made on July 27th 2021 and the most recent update occurring October 26th 2022. This information can be sourced from clinicaltrials.gov."

"This trial is attempting to recruit sixty children and adolescents, aged between six and seventeen years old, suffering from Attention Deficit Disorder (ADD). Applicants must meet the following criteria: Be taking a single psychostimulant medication for ADD with an inadequate response as defined by investigator-rated ADHD-RS-5 Total score ≥24 and CGI-S score ≥3; be male or female aged 6 -17 at screening; have lived in same residence for past 6 months prior to screening; confirmed diagnosis of ADD through Mini International Neuropsychiatric Interview for Children and Adolescents (MINI-KID); remain on stable psychost"

"Taking into account that this treatment is in its fourth phase of testing, our team at Power assigned a score of 3 to Open-Label Treatment's safety."

"This research project is seeking individuals between the ages of 6 and 17 years old."